Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
Recruiting now NCT05313815
Run by University Health Network, Toronto · for 18 and older · Men
What this study is about
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age > 18 years.
- Able to provide informed consent.
- Histologic diagnosis of prostate adenocarcinoma.
- ECOG performance status 0-1.
- High-risk localized disease by NCCN criteria (>cT3, Grade group >4, or PSA >20 ng/mL) or clinical N1 disease.
- Clinical M0 by conventional imaging (computed tomography (CT) and bone scan (BS)) and/or molecular imaging (prostate specific membrane antigen (PSMA)- positron emission tomography (PET))
🚫 You may not be able to join if…
- Prior pelvic radiotherapy.
- Contraindications to radiotherapy
Where this trial is running
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
Who to contact
Rachel Glicksman, MD · 416-946-4486 · rachel.glicksman@rmp.uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05313815.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.